Wise Medical Reports RMB 400 Million Revenue in 2024 Amid Strategic Product Expansion

Registration: First Global Cardiovascular Conference | Highlight

Call for Partners: 2025 Global Surgical Robotics Conference

April 24, 2024VISHEERelease of the 2024 Annual Report and the First Quarter Report of 2025.

# Financial Report Data

Company's Revenue in 2024400 millionYuan (YoY -13.45%), Net Profit Attributable to Shareholders102 millionYuan (YoY -25.16%), Non-GAAP Net Profit Attributable to Shareholders83 millionYuan (YoY -31.72%).

Based on this calculation,Revenue of 108 million yuan was achieved in Q4 2024 (a year-on-year decrease of 16.98%).Net profit attributable to shareholders: 0.24 billion yuan (a year-on-year decrease of 31.16%), non-recurring net profit attributable to shareholders: 0.15 billion yuan (a year-on-year decrease of 51.65%).

In 2024, the two products of VISHEE's energy-based medical aesthetics devices, the body-sculpting magnetic stimulation device and the high-frequency electrocautery device, both achieved excellent sales results. Meanwhile, the navigated transcranial magnetic stimulation device and the picosecond laser treatment device successfully obtained certification, further enriching the company’s premium product portfolio.

Split in 2024

By Business:Magnetic stimulation revenue was 172 million yuan (a year-on-year decrease of 13.92%); electrical stimulation revenue was 37 million yuan (a year-on-year decrease of 41.75%); electrophysiology revenue was 65 million yuan (a year-on-year increase of 0.25%); consumables and accessories revenue was 79 million yuan (a year-on-year increase of 4.14%); laser and radiofrequency revenue was 30 million yuan (a year-on-year decrease of 20.87%).

The Company Achieved Revenue in the First Quarter of 202596 millionCNY (YoY +9.40%)Net profit attributable to母公司 shareholders was 0.33 billion yuan (up 52.71% year-on-year), and non-recurring net profit attributable to母公司 shareholders was 0.31 billion yuan (up 58.96% year-on-year).

# About VISHEE

VISHEE was founded in 2001, with its headquarters located in Nanjing, Jiangsu Province, China. It is a technology innovation-driven medical device company, as well as a national high-tech enterprise, a STAR Market listed company, and a national-level specialized and new "little giant" enterprise. The company focusesEngaged in the research, development, production, and sales of rehabilitation medical devices, covering 30 provinces, municipalities, and autonomous regions in China, with terminal sales reaching over 8,000 medical institutions.

VISHEE's products mainly cover four major fields: mental rehabilitation, neurological rehabilitation, motor rehabilitation, and pelvic floor and postpartum rehabilitation.The company adopts a "direct sales + distribution" business model, deeply binding end customers, and its medical aesthetic products are quickly commercialized through professional institutions.

The core driving force of VISHEE lies inTechnological innovation and the improvement of the product matrix.The company owns magnetic stimulation, electrical stimulation, electrophysiology, rehabilitation robots, radio frequency, laser, etc.Six Major Technology Platforms, and continuously expand core technologies. For instance, its pelvic floor magnetic stimulator and navigated transcranial magnetic stimulator reach international standards in precise positioning and treatment efficiency. Moreover, the company is actively entering the medical aesthetics sector, with its med-aesthetic division becoming a key growth driver in 2024.